Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

PsyBio Therapeutics sees its shares debut on the OTCQB Venture Market in the US

CEO Evan Levine called the move “an important milestone" towards broadening its market presence across the United States

PsyBio Therapeutics Corp (CVE:PYSB) (OTCQB:PSYBF) (FRA:PSYB) has announced its uplisting to the OTCQB Venture Market on July 14.

Shares of the Ohio and Florida-based psychedelics company will trade on the US exchange under the symbol ‘PSYBF.’

READ: PsyBio Therapeutics grows intellectual property portfolio with filing of new patent application

PsyBio CEO Evan Levine called the move “an important milestone towards broadening our market presence across the United States as we engage with this significant shareholder audience."

Levine added: "Listing on the OTCQB positions PsyBio with increased visibility among the US-based investment community and improved liquidity for our current and prospective shareholders."

PsyBio also said that it has applied for DTC eligibility in the US to facilitate electronic settlement of its shares.

In a statement, the company said that the eligibility will help to enhance liquidity and offer a more “convenient” trading experience.

Shares of PsyBio also trade on the TSX Venture Exchange and the Frankfurt Stock Exchange.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK